All questions
Safety: Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) in chronic obstructive pulmonary disease 8 questions · 5 sources
Safety questions that apply to every indication of Trelegy Ellipta are on Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder), all indications: Safety .
Side effects What side effects were reported with Trelegy in the IMPACT COPD trial? Note: The table text lists each row's values in the header order: TRELEGY 100 (n=4151), BREO 100 (n=4134), ANORO (n=2070), as percentages. Pneumonia counted as an adverse event of special interest was 8% for TRELEGY 100.
What side effects were reported with Trelegy in the FULFIL trial? Note: Each row lists TRELEGY 100 first and SYMBICORT TURBUHALER 400/12 second, as percentages. In the pneumonia table the 52-week row covers the extension population. SYMBICORT TURBUHALER 400/12 is a non-US budesonide/formoterol formulation.
What are the most common side effects of Trelegy for COPD? “In subjects with COPD, the most common adverse reactions (≥1% and more common than placebo + FF/VI) reported in two 12-week clinical trials with UMEC + FF/VI, the components of TRELEGY, (and placebo + FF/VI) were: headache, 4% (3%); back pain, 4% (2%); dysgeusia, 2% (<1%); diarrhea, 2% (<1%); cough, 1% (<1%); oropharyngeal pain, 1% (0%); and gastroenteritis, 1% (0%).” (opens the source at this quote in a new tab) Copy Flag
“COPD: Most common adverse reactions (incidence ≥1%) are upper
respiratory tract infection, pneumonia, bronchitis, oral candidiasis,
headache, back pain, arthralgia, influenza, sinusitis, pharyngitis, rhinitis,
dysgeusia, constipation, urinary tract infection, diarrhea, gastroenteritis,
oropharyngeal pain, cough, and dysphonia. (6.1)” (opens the source at this quote in a new tab) Copy Flag
Note: The first passage gives rates from two 12-week trials of umeclidinium added to fluticasone furoate/vilanterol, with the placebo + FF/VI rate in parentheses. The second is the label summary, which includes the 52-week trial.
What are the long-term side effects of Trelegy for COPD? “In addition to the adverse reactions shown in table above, adverse reactions occurring in ≥1% of the subjects with COPD treated with TRELEGY 100/62.5/25 (n=4151) for up to 52 weeks also included URTI, pneumonia, bronchitis, oral candidiasis, arthralgia, influenza, sinusitis, pharyngitis, rhinitis, constipation, UTI, and dysphonia.” (opens the source at this quote in a new tab) Copy Flag
Note: The label's warnings on bone mineral density, glaucoma, and cataracts concern long-term ICS use; see the bone loss and glaucoma questions.
Warnings Does Trelegy increase the risk of pneumonia in COPD? “In a 52-week trial of subjects with COPD (N = 10,355), the incidence of pneumonia was 8% for
TRELEGY ELLIPTA 100/62.5/25 mcg (n = 4,151), 7% for fluticasone furoate/vilanterol
100/25 mcg (n = 4,134), and 5% for umeclidinium/vilanterol 62.5/25 mcg (n = 2,070). Fatal
pneumonia occurred in 12 of 4,151 patients (0.35 per 100 patient-years) receiving TRELEGY
ELLIPTA 100/62.5/25 mcg; 5 of 4,134 patients (0.17 per 100 patient-years) receiving
fluticasone furoate/vilanterol 100/25 mcg; and 5 of 2,070 patients (0.29 per 100 patient-years)
receiving umeclidinium/vilanterol 62.5/25 mcg.” (opens the source at this quote in a new tab) Copy Flag
Note: The 52-week trial is IMPACT (Trial 3 of the Prescribing Information).
Can Trelegy cause heart problems in COPD? “In a 52-week trial of subjects with COPD, the exposure-adjusted rates for any on-treatment
major adverse cardiac event, including non-fatal central nervous system hemorrhages and
cerebrovascular conditions, non-fatal myocardial infarction (MI), non-fatal acute MI, and
adjudicated on-treatment death due to cardiovascular events, was 2.2 per 100 patient-years for
TRELEGY ELLIPTA (n = 4,151), 1.9 per 100 patient-years for fluticasone furoate/vilanterol
100/25 mcg (n = 4,134), and 2.2 per 100 patient-years for umeclidinium/vilanterol 62.5/25 mcg
(n = 2,070). Adjudicated on-treatment deaths due to cardiovascular events occurred in 20 of
4,151 patients (0.54 per 100 patient-years) receiving TRELEGY ELLIPTA; 27 of 4,134 patients
(0.78 per 100 patient-years) receiving fluticasone furoate/vilanterol; and 16 of 2,070 patients
(0.94 per 100 patient-years) receiving umeclidinium/vilanterol.” (opens the source at this quote in a new tab) Copy Flag
Note: The 52-week trial is IMPACT (Trial 3 of the Prescribing Information).
Does Trelegy cause bone loss in COPD? “Decreases in bone mineral density (BMD) have been observed with long-term administration of
products containing ICS. The clinical significance of small changes in BMD with regard to
long-term consequences such as fracture is unknown. Patients with major risk factors for
decreased bone mineral content, such as prolonged immobilization, family history of
osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of
drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored
and treated with established standards of care. Since patients with COPD often have multiple risk
factors for reduced BMD, assessment of BMD is recommended prior to initiating TRELEGY
ELLIPTA and periodically thereafter. If significant reductions in BMD are seen and TRELEGY
ELLIPTA is still considered medically important for that patient’s COPD therapy, use of therapy
to treat or prevent osteoporosis should be strongly considered.” (opens the source at this quote in a new tab) Copy Flag
Can Trelegy be started while COPD is rapidly worsening?